AASDHPPT and breast carcinoma: Comparison with the FDA‐approved anticancer agent salinomycin (FDA ODD: HSB‐1216), an apoptosis‐inducing ionophore that has been shown to be effective at targeting breast cancer stem cells,[42] revealed that ACPs have similar activity, but superior selectivity toward breast cancer cells (Figure S3, Supporting Information).